Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.35 |
| ▸ | DRD3 | P35462 | 8/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873054 | 0.91 | PIM1 (0.40) | DRD2DRD3PIM1L3MBTL1MEN1 | |
| SCHEMBL5770403 | 0.89 | PIM1 (0.42) | NAMPTPIM1MEN1ALDH1A1HTT | |
| SCHEMBL5873145 | 0.87 | TACR3 (0.40) | L3MBTL1MEN1ALDH1A1KMT2ATACR3 | |
| SCHEMBL5872958 | 0.86 | MKNK1 (0.43) | PIM1MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL5872913 | 0.86 | DYRK1A (0.40) | NAMPTPIM1MEN1ALDH1A1HTT | |
| SCHEMBL5873025 | 0.85 | ALDH1A1 (0.43) | NAMPTPIM1MEN1ALDH1A1HTT | |
| SCHEMBL5872792 | 0.85 | TSHR (0.41) | PIM1MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL5873133 | 0.85 | TACR3 (0.42) | L3MBTL1MEN1ALDH1A1KMT2ATACR3 | |
| SCHEMBL5873052 | 0.85 | HCRTR1 (0.34) | ALDH1A1HCRTR1HCRTR2KDM5A | |
| SCHEMBL5873165 | 0.84 | SLC6A7 (0.41) | NAMPTPIM1MEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | DRD2 4757/4885DRD3 4601/4885NAMPT 975/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | DRD2 4757/4885DRD3 4601/4885NAMPT 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.